Open Access<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>
Author(s) -
Jian-De Cheng,
Lixun Chai,
Zhiping Zhao,
Ya Hao,
Shuo Li
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s253366
Subject(s) - medicine , oncology , adverse effect , proportional hazards model , lung cancer , response evaluation criteria in solid tumors , progression free survival , multivariate analysis , progressive disease , disease , chemotherapy
The aim of this study was to investigate the efficacy and safety of anlotinib for patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard regimens in real world situations and the preliminary analysis of an efficacy predictor.